Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Ameriprise Financial Inc.

Ameriprise Financial Inc. increased its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 16.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,277 shares of the biotechnology company’s stock after buying an additional 1,839 shares during the period. Ameriprise Financial Inc.’s holdings in Grifols, were worth $251,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Huntington National Bank boosted its stake in Grifols, by 1.2% in the first quarter. Huntington National Bank now owns 6,704 shares of the biotechnology company’s stock worth $127,000 after buying an additional 77 shares during the last quarter. Advisory Services Network LLC bought a new stake in Grifols, during the first quarter valued at about $143,000. Quadrant Capital Group LLC boosted its stake in Grifols, by 168.1% in the first quarter. Quadrant Capital Group LLC now owns 11,990 shares of the biotechnology company’s stock valued at $220,000 after buying an additional 7,517 shares during the last quarter. Atria Investments LLC boosted its stake in Grifols, by 9.6% in the first quarter. Atria Investments LLC now owns 11,702 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 1,023 shares during the last quarter. Finally, Opus Point Partners Management LLC boosted its stake in Grifols, by 40.2% in the fourth quarter. Opus Point Partners Management LLC now owns 16,613 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 4,764 shares during the last quarter. 22.65% of the stock is currently owned by institutional investors.

Grifols, S.A. (NASDAQ GRFS) traded down 0.79% during mid-day trading on Friday, hitting $20.12. The company had a trading volume of 228,892 shares. The company has a market capitalization of $27.49 billion, a P/E ratio of 41.83 and a beta of 0.97. Grifols, S.A. has a 52-week low of $14.27 and a 52-week high of $22.83. The company has a 50-day moving average price of $20.65 and a 200 day moving average price of $19.84.

ILLEGAL ACTIVITY NOTICE: “Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Ameriprise Financial Inc.” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/08/19/grifols-s-a-nasdaqgrfs-shares-bought-by-ameriprise-financial-inc-updated-updated-updated.html.

Several research analysts have commented on GRFS shares. BidaskClub raised shares of Grifols, from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Zacks Investment Research raised shares of Grifols, from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, July 4th. Bank of America Corporation reissued a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) lowered shares of Grifols, from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $24.00.

About Grifols,

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Institutional Ownership by Quarter for Grifols, (NASDAQ:GRFS)

What are top analysts saying about Grifols S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols S.A. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit